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Summary
Specific inhibitors of COX-2 have been associated with increased risk for cardiovascular complications. These agents
reduce prostacyclin (PGI2) without affecting production of thromboxane (Tx) A2. While this abnormal pattern of eicosanoid
generation has been implicated in the development of vascular disease associated with COX-2 inhibition, its role in the
development of hypertension, the most common cardiovascular complication associated with COX-2 inhibition, is not
known. We report here that mice lacking the receptor for PGI2 (IPKOs) develop salt-sensitive hypertension, cardiac hyper-
trophy, and severe cardiac fibrosis. Coincidental deletion of the TxA2 (TP) receptor does not prevent the development of
hypertension, but cardiac hypertrophy is ameliorated and fibrosis is prevented in IPTP double knockouts (DKOs). Thus,
deletion of the IP receptor removes a constraint revealing adverse cardiovascular consequences of TxA2. Our data suggest
that adjuvant therapy that blocks unrestrained Tx actions might protect against end-organ damage without affecting blood
pressure in patients taking COX-2 inhibitors.Introduction
In the APPROVe study, an increased rate of cardiovascular
events in patients treated with the specific COX-2 inhibitor ro-
fecoxib led to its withdrawal from the market (FitzGerald, 2004;
http://www.vioxx.com). Although the results leading to with-
drawal of rofecoxib were unequivocal, they involved a relatively
small number of individuals—an excess of just 20 events in a
trial of 2,600 subjects. Like traditional nonsteroidal anti-inflam-
matory drugs (NSAIDs), which inhibit coincidentally both COX-1
and COX-2, selective inhibitors of COX-2 elevate blood pres-
sure (Aw et al., 2005). However, experiments in mice suggest
that the propensity to elevate blood pressure may relate not
just to inhibition of COX-2 but also to the selectivity with which
it is attained (Athirakul et al., 2001; Qi et al., 2002). Hyperten-
sion was detected early on in the trial of rofecoxib, and the
development of excess cardiovascular events was not ob-
served until 18 months into the trial. While the cardiovascular
consequences of even small increases in blood pressure have
been clearly documented (Chobanian et al., 2003), a direct re-
lationship with hypertension and cardiovascular outcomes as-
sociated with COX-2 inhibitors has yet to be established.
Moreover, the precise prostanoid pathways responsible for
blood-pressure elevations caused by COX-2 inhibitors are not
clear.
In humans, COX-2 inhibitors reduce prostacyclin levels with-
out affecting generation of thromboxane (Tx) A2 (McAdam et
al., 1999), which in the basal state appears to depend primarily
on COX-1 pathways in platelets. This altered profile of prostan-CELL METABOLISM : SEPTEMBER 2005 · VOL. 2 · COPYRIGHT © 2005oid synthesis may be a cardiovascular hazard, and experi-
ments in mouse models suggest that reduced prostacyclin
(PGI2) signaling when Tx actions are preserved promotes ath-
erogenesis (Egan et al., 2004) and vascular injury (Cheng et
al., 2002). However, the contribution of this altered profile of
eicosanoids to the development of hypertension is not clear.
Based on its actions as a vasodilator and natriuretic agent
(Hilchey and Bell-Quilley, 1995; Hill and Moncada, 1979), inhi-
bition of PGI2 synthesis could play a causal role in the elevation
in blood pressure commonly seen in patients treated with these
agents. However, previous studies in mouse models have sug-
gested that prostacyclin may have little effect on resting blood
pressure (Cheng et al., 2002; Murata et al., 1997; Watanabe et
al., 2005; Xiao et al., 2001) or may actually promote hyperten-
sion caused by renal artery stenosis (Fujino et al., 2004).
To address the consequences of suppression of PGI2 on blood
pressure and end-organ damage, we generated mice lacking the
IP receptor for PGI2 on an inbred, 129/SvEv background. In this
setting, we find that the absence of IP receptors is sufficient to
cause hypertension with cardiac hypertrophy and fibrosis. Fur-
thermore, when IP receptors are absent, we find that unrestrained
actions of Tx acting through its TP receptor accentuate the inten-
sity of hypertension-induced cardiac damage.
Results
Salt-sensitive hypertension in IPKOs
(Figure 1A) In mice fed a conventional 0.4% NaCl diet, we
found that blood pressures were significantly elevated in theELSEVIER INC. DOI 10.1016/j.cmet.2005.08.005 201
S H O R T A R T I C L EFigure 1. Elevated blood pressures and cardiac hypertrophy in IPKO mice
A) Blood pressures were measured in wt (n = 10; open diamonds with dashed
line) and IPKO mice (n = 12; closed squares with solid line) during sequential
feeding of normal (0.4% NaCl), low (<0.02% NaCl), and high (6% NaCl) salt diets.
(*p = 0.02 versus wt normal salt; **p < 0.05 versus IPKO normal salt; †p < 0.05
versus wt High Salt; ‡p < 0.01 versus IPKO normal salt; §p < 0.05 versus wt
normal salt).
B) Heart-to-bodyweight ratios were measured in separate groups of wt (white
bars) and IPKO (black bars) mice at 3 (n = 13), 6 (n = 18), and 17 months of age
(n = 12). (*p < 0.05 versus Ip+/+.)
Error bars represent standard error of the mean (SEM).IPKOs (126 ± 2 mm Hg; n = 12) compared to wild-type (wt)
controls (118 ± 2 mm Hg; p = 0.02, n = 10). We next evaluated
the effects of altering dietary sodium intake on blood pressures
in the two groups. There was a modest, nonsignificant fall in
blood pressure (Figure 1A) in wt mice from 119 ± 5 to 114 ± 4
mm Hg (p = 0.18) after 3 weeks on a low-salt diet (<0.02 NaCl).
By contrast, there was a more marked and significant fall in
blood pressures in the IPKOs from 129 ± 5 to 119 ± 5 mm Hg
(p < 0.05) during low-salt feeding. Moreover, at the end of the
low-salt feeding period, blood pressures in the wt and IPKOs
were not significantly different (p = 0.42). Three weeks of feed-
ing the high-salt diet (6% NaCl) caused blood pressure to in-
crease significantly in the wts to 137 ± 5 mm Hg (p < 0.05),
consistent with previous reports of sodium sensitivity in this
strain (Ryan et al., 2002; Wang et al., 2002). Moreover, this diet
caused an even larger (p < 0.05) increase in blood pressure in
the IPKOs to 157 ± 6 mm Hg (p < 0.01).
Cardiac hypertrophy in IP-deficient mice
To seek evidence of end-organ damage from chronic hyperten-
sion, we compared heart weights between Ip−/− and Ip+/+ mice202at 3, 6, and 17 months of age. While heart-to-body weight ra-
tios were similar in 3-month-old Ip+/+ and Ip−/− mice (5.0 ± 0.1
versus 5.0 ± 0.2), they were significantly increased (Figure 1B
and Table 1) in the IPKOs by 6 months of age (6.3 ± 0.1 versus
5.3 ± 0.3; p < 0.05). Persistent cardiac hypertrophy was appar-
ent in IPKOs by 17 months of age (7.2 ± 0.2 versus 6.3 ± 0.3;
p < 0.05). Echocardiography was performed in conscious,
6-month-old mice to determine whether IP deficiency was as-
sociated with defects in cardiac function. Fractional shortening
was virtually identical in wt (0.65 ± 0.02) and IPKOs (0.60 ±
0.05; p = 0.42) as were LV dimensions (3.28 ± 0.13 versus
3.41 ± 0.06 mm for LVEDD and 1.16 ± 0.06 versus 1.36 ± 0.18
mm for LVESD). Thus, IP-deficient mice have cardiac hypertro-
phy with normal chamber dimensions and preserved systolic
function. This phenotype of concentric LV hypertophy with pre-
served systolic function is similar to that seen in patients with
chronic hypertension where LVH is a potent risk factor for car-
diovascular events such as MI and stroke (Verdecchia et al.,
2001).
IP deficiency causes cardiac fibrosis
To develop a more complete characterization of cardiac dam-
age associated with IP deficiency, we also examined cardiac
histopathology, comparing wt and IP-deficient mice. Broad
areas of interstitial fibrosis were evident throughout the left
ventricle in IPKOs (Figure 2A), but there was no evidence of
cardiac fibrosis in wts (Figure 2B). Indeed, myocardial fibrosis
was detectably increased in the IPKOs as early as 6 months of
age (4.9% ± 1.4% versus 1.6% ± 0.1%; p < 0.001) in the
IPKOs (Figure 2C). These abnormalities were even more pro-
nounced in the 17-month-old cohort (5.8% ± 1.1% versus
1.9% ± 0.2%; p < 0.001). Fibrosis was confined to the left
ventrical as we did not observe lesions in the right ventricle of
the IPKOs. Moreover, the extent of interstitial cardiac fibrosis
did not correlate with the degree of cardiac hypertrophy.
Renin and aldosterone levels are not affected
by IP deficiency
Because the IP receptor is a physiological regulator of renin
(Fujino et al., 2004) and activation of the renin-angiotensin-
aldosterone system can promote the development of cardiac
hypertrophy and fibrosis, we compared renin and aldosterone
levels in IP+/+ and IP−/− mice. Renin mRNA levels, measured
by RT-PCR from total RNA isolated from kidneys after feeding
a control (0.4% NaCl) diet, tended to be slightly lower but not
significantly different in IPKOs (110 ± 19 pg/µg total RNA; n =
10) compared to wt controls (126 ± 29 pg/µg total RNA; n =
13). Urinary aldosterone excretion was virtually identical be-
tween the two groups (15 ± 2.3 versus 14.4 ± 1.4 ng/mg creati-
nine; n = 7 wt versus n = 6 IPKO). Therefore, it is unlikely that
enhanced activity of the renin-angiotensin-aldosterone system
can explain the exaggerated cardiac hypertrophy and fibrosis
observed in the IP-deficient mice.
Antihypertensive therapy prevents cardiac hypertrophy
and fibrosis in IP-deficient mice
To determine whether cardiac hypertrophy and fibrosis resulted
from the increase in blood pressure, we treated the IPKOs with
hydralazine, a vasodilator antihypertensive agent, from 3 to 6
months of age. Compared to pretreatment values, administra-
tion of hydralazine significantly lowered blood pressures inCELL METABOLISM : SEPTEMBER 2005
Hypertension and heart fibrosis in IP deficiencyTable 1. Heart and body weights
Age (months) 3 6 17
Genotype IP−/− IP+/+ IP−/− IP+/+ IP−/− IP+/+
n = 6 n = 7 N = 6 n = 12 n = 6 n = 6
Body weight (g) 27.1 ± 1 25.7 ± 0.4 30.5 ± 0.4 30 ± 2.4 32.2 ± 1.4 31.4 ± 1.2
Heart weight (mg) 135 ± 7 129 ± 4 191 ± 5a,b 155 ± 13 232 ± 8a 198 ± 8
H/B ratio (mg/g) 5.0 ± 0.1 5.0 ± 0.1 6.3 ± 0.1a 5.2 ± 0.4 7.2 ± 0.2a 6.3 ± 0.3
a p < 0.05 versus IP+/+.
b p < 0.01 versus IP+/+.inbred IPTP DKO 129/SvEv mice. Coincidental deletion of the
Figure 2. Myocardial fibrosis in IP-deficient mice
A) Representative Masson trichrome-stained sec-
tion of the left ventricle of a 17-month-old IP-defi-
cient mouse showing prominent myocardial fibrosis.
The black line represents 100 µm.
B) Similarly stained section of a 17-month-old heart
from a wt control showing normal myocardium with-
out fibrosis.
C) Morphometric analysis of the extent of cardiac
fibrosis in wt (white bars) and IPKO (black bars)
mice at 3 (n = 13), 6 (n = 18), and 17 months of age
(n = 12). (*p < 0.01 versus wt.) Error bars represent
SEM.
TxA2). There was no significant difference in the levels of uri-IPKOs (130 ± 3 mm Hg versus 113 ± 2 mm Hg; p < 0.0001, n =
7) as expected. The blood pressures achieved in hydralazine-
treated animals were equivalent to that of wt 129/SvEv mice
(113 ± 2 versus 120 ± 2 mm Hg; n = 6). Reducing blood pres-
sure to normal levels prevented both the increase in heart
weight and the cardiac fibrosis seen in untreated IP-deficient
mice (Figure 3), indicating their dependence on elevated
blood pressure.
TP-receptor activation contributes to end-organ
injury in IP deficiency
The predominant suppression of PGI2 synthesis and sparing of
TxA2 synthesis caused by COX-2 inhibitors has been associ-
ated with increased cardiovascular risk (FitzGerald, 2004; Fitz-
Gerald and Patrono, 2001). To determine whether hypertension
and the cardiovascular phenotype of IP deficiency resulted
from unrestrained activation of the TP receptor, we generatedCELL METABOLISM : SEPTEMBER 2005TP did not rescue the hypertensive phenotype of IP deficiency,
as there was no difference in blood pressures in the IPTP
double knockouts (DKOs) (134 ± 5 mm Hg; n = 7) and the
IPKOs (130 ± 3 mm Hg; n = 7). However, despite their similar
blood pressures, both heart weights (5.8 ± 0.1 versus 6.3 ± 0.1
mg/gm; p < 0.01) and the extent of cardiac fibrosis (1.63% ±
0.2% versus 4.9% ± 1.4%; p < 0.01) were limited significantly
by combined IPTP receptor deficiency compared to IP deletion
alone (Figure 3). Indeed, the quantitative scores for cardiac fi-
brosis were virtually identical in the IPTP DKOs and the wt con-
trols (1.6% ± 0.1% versus 1.6% ± 1%; p = NS). Heart-to-body
weight ratios in mice with isolated TP deficiency were similar
to wt controls (5.0 ± 0.2 versus 5.2 ± 0.1 mg/gm), and the
hearts were pathologically indistinguishable.
To determine whether the generation of TxA2 might be en-
hanced in hypertensive, IP-deficient mice, we measured uri-
nary excretion of thromboxane (Tx) B2 (a stable metabolite of203
S H O R T A R T I C L EFigure 3. Morphometric analysis of cardiac fibrosis in 6-month-old mice
The extent of cardiac fibrosis was determined as described in groups of
6-month-old wt mice (white bar; n = 12), IPKO mice (black bar; n = 6), IPKO mice
that had been treated with hydralazine for 3 months (striped bar; n = 7), and mice
with combined IP and TP deficiency (IPTP DKOs) (gray bar; n = 10). (*p < 0.001
versus wt; †p < 0.05 versus IPKO + hydralazine; ‡p < 0.01 versus IPTP DKO).
Error bars represent SEM.nary TxB2 excretion between hypertensive IPKOs (4.7 ± 1.1 ng/
mg creatinine; n = 11) and normotensive wt controls (5.6 ± 1
ng/mg creatinine; n = 10). Thus, the absence of IP receptors
and/or hypertension associated with IP deficiency do not
cause enhanced thromboxane generation.
Discussion
Prostanoids have potent actions to regulate vascular tone and
renal sodium handling, thereby impacting control of blood
pressure (Smith, 1992). The most compelling evidence sup-
porting a role for prostanoids in blood pressure homeostasis
comes from clinical experiences with NSAIDs. In susceptible
patients, inhibition of prostanoid generation by NSAIDs causes
sodium retention with edema and hypertension (Gurwitz et al.,
1994; Johnson et al., 1994; Pope et al., 1993). In addition,
NSAIDs may interfere with the actions of antihypertensive ther-
apies, particularly loop diuretics and ACE inhibitors (Conlin et
al., 2000; Pope et al., 1993). These effects were originally iden-
tified in patients taking nonselective COX inhibitors. However,
sodium retention, hypertension, and blunted actions of antihy-
pertensive agents are also commonly seen in patients taking
COX-2 inhibitors (Aw et al., 2005). Moreover, clinical reports
and animal studies suggest that specific inhibition of COX-2
may have a greater propensity to increase blood pressure than
simultaneous inhibition of both COX-1 and COX-2 (Athirakul et
al., 2001; Aw et al., 2005; Qi et al., 2002). Insofar as the effects
of COX inhibition upon blood pressure homeostasis are a con-
sequence of inhibiting of prostanoid synthesis, it follows that
these actions must result from direct interruption of signaling
through one or more prostanoid receptors. Yet, a precise link-
age between inhibition of specific prostanoid products and the
development of NSAID-associated hypertension has not been
clearly established.
Administration of COX-2 to humans is associated with re-
duced generation of the vasodilator PGI with preserved syn-2
204thesis of the vasoconstrictor prostanoid TxA2 (McAdam et al.,
1999). Along with its vasodilator properties, PGI2 also pro-
motes sodium and water excretion (Hilchey and Bell-Quilley,
1995; Hill and Moncada, 1979). Accordingly, reduced genera-
tion of PGI2 could contribute to sodium retention and blood-
pressure elevation associated with COX-2 inhibition. However,
the potential impact of PGI2 on blood pressure is complex.
PGI2 acting through the IP receptor at the juxtaglomerular ap-
paratus (JGA) is an important stimulatory pathway for release
of renin, the rate-limiting enzyme in generation of angiotensin
II (Gerber et al., 1979). Accordingly, activation of IP receptors
in some circumstances could promote the development of hy-
pertension. In this regard, recent studies by Fujino et al. sug-
gest that the IP receptors contribute to the pathogenesis of
hypertension caused by renal artery stenosis (Fujino et al.,
2004).
The capacity of COX inhibitors to cause hypertension is well
documented. However, NSAIDs only cause significant eleva-
tions in blood pressure in a subset of susceptible patients, in-
cluding those with pre-existing hypertension, on active antihy-
pertensive therapy or with specific risk factors for hypertension
(Gurwitz et al., 1994; Johnson et al., 1994; Pope et al., 1993).
In this regard, exaggerated blood pressure response to sodium
loading and depletion, also known as salt sensitivity, is an im-
portant risk factor for hypertension in humans (Weinberger,
1996). As mice of the 129/SvEv strain have salt sensitivity
(Ryan et al., 2002; Wang et al., 2002), we reasoned that this
strain of mice would be a useful platform for modeling NSAID-
induced hypertension. To this end, we generated inbred IP-
deficient mice on the 129/SvEv background and found that
these animals have significant elevations in blood pressure.
Moreover, the tendency for sodium sensitivity in wt 129/SvEv
mice is markedly accentuated by IP deficiency, indicating a
critical role for PGI2 in regulating pressure-natriuresis relation-
ships.
Our findings differ from previous studies of blood pressure
in IP-deficient mice (Cheng et al., 2002; Fujino et al., 2004;
Murata et al., 1997; Watanabe et al., 2005; Xiao et al., 2001).
For example, IP-deficient mice generated on an inbred C57BL/6
background had either normal or reduced blood pressures
(Fujino et al., 2004; Watanabe et al., 2005). In contrast to the
129 strain, C57BL/6 mice are resistant to sodium-dependent
blood-pressure changes (Ryan et al., 2002; Wang et al., 2002).
Therefore, this difference in genetic backgrounds may explain
the different blood-pressure responses in these studies. None-
theless, in the study by Watanabe and associates, female
C57BL/6 mice with IP deficiency acquire a sodium-sensitive
phenotype (Watanabe et al., 2005), consistent with our asser-
tion that PGI2 is an important regulator of renal sodium excre-
tion. These differing susceptibilities to prostanoid-dependent
hypertension among inbred mouse strains are consistent with
the variable risk for NSAID-induced hypertension across hu-
man populations. Furthermore, these findings suggest that ge-
netic factors might contribute to determining susceptibilities to
this disorder in patients. Accordingly, understanding the nature
of these strain differences may provide insights into the mech-
anisms of NSAID-associated hypertension in humans.
Hypertension in IP-deficient mice is associated with the de-
velopment of robust cardiac hypertrophy and fibrosis. The
characteristics of left ventricular hypertrophy with preservedCELL METABOLISM : SEPTEMBER 2005
Hypertension and heart fibrosis in IP deficiencysystolic function in IP-deficient mice are very similar to LVH in
humans with chronic hypertension where the presence of LVH
is a potent risk factor for cardiovascular morbidity and mortality
(Verdecchia et al., 2001). Myocardial fibrosis is also associated
with poor cardiovascular outcomes (Klug et al., 1993; Weber
and Brilla, 1991). Thus, in this mouse model, isolated absence
of IP receptors is associated with hypertension and cardiac
abnormalities that would be expected to confer cardiovascular
risk in humans. While it is not clear whether hypertension and
its accompaniments play a role in the cardiovascular risk asso-
ciated with COX-2 inhibitors, a number of the patients in the
APPROVe trial developed hypertension, and the excess in CV
events in the patients receiving COX-2 inhibitor did not be-
come apparent until more than 18 months into the study. Such
a delayed appearance of risk might be expected if hyperten-
sion is a contributor.
Relative to other mouse models, the degree of cardiac fibro-
sis in the IPKOs was out of proportion to their level of blood-
pressure elevation. Nonetheless, the pathogenesis of these ab-
normalities clearly depends on concomitant hypertension since
lowering blood pressure with hydralazine completely prevented
both hypertrophy and fibrosis. Thus, elevated blood pressure is
essential for the development of cardiac injury in IP deficiency.
Insofar as our findings might relate to patients with predomi-
nant inhibition of PGI2 from COX-2 inhibitors, this would sug-
gest that control of hypertension could ameliorate this ten-
dency for exaggerated end-organ injury. Nonetheless, the
development of florid end-organ damage in this circumstance
is more complex than a simple response to elevated blood
pressure. Our data indicate a direct role for TP signaling to
promote cardiovascular pathology associated with IP defi-
ciency. That is, when hypertension associated with IP defi-
ciency is not controlled, unrestrained activation of the TP re-
ceptor promotes cardiac fibrosis. This finding is consistent with
observations in other models showing that activation of the TP
receptor can promote end-organ injury (Cheng et al., 2002;
Francois et al., 2004).
TP receptors contribute to blood-pressure elevation in ex-
perimental models of hypertension (Francois et al., 2004). Yet,
concomitant deletion of TP receptors does not rescue the hy-
pertensive phenotype of IP deficiency. Despite their similar
blood pressures, cardiac hypertrophy and fibrosis are amelio-
rated in mice with concomitant deletion of both IP and TP re-
ceptors compared to those with IP deficiency alone. Thus, de-
letion of the IP receptor removes a constraint revealing potent
effects of TxA2 to promote cardiac pathology. However, this is
not due to exaggerated generation of TxA2 associated with IP
deficiency and its associated hypertension. These findings pro-
vide additional evidence to support the thesis that the actions
of COX-2 inhibitors to suppress PGI2 synthesis without affect-
ing TxA2 levels have maladaptive consequences in the cardio-
vascular system. Such an effect would not be anticipated with
conventional NSAIDs that cause more global inhibition of both
PGI2 and TxA2. As TxA2 agonists promote inflammation
(Thomas et al., 2003) and fibrosis (Bruggeman et al., 1993) in
cell culture systems independent of any hemodynamic effects,
these pathways may contribute to exaggerated cardiovascular
injury associated with unrestrained activation of TP receptors
in IP deficiency.
We have relied exclusively on tail-cuff measurements to de-CELL METABOLISM : SEPTEMBER 2005termine blood pressures in this study. In our view, the tail-cuff
technique has the major advantage of providing blood-pres-
sure measurements in conscious mice using a completely non-
invasive approach. However, there is evidence that this method
may induce some stress in mice (Gross and Luft, 2003), and it
is not as sensitive for blood-pressure measurement as radiote-
lemetry approaches. Nonetheless, previous studies have
clearly documented its validity and tight correlations with the
other available invasive approaches (Ito et al., 1995; Krege et
al., 1995), including radiotelemetry (Crowley et al., 2005; Wong
et al., 2002).
In summary, our study has several important implications.
Firstly, the propensity for sodium retention and hypertension
seen in patients taking COX-2 inhibitors is mechanistically con-
sistent with suppression of PGI2. Although there is evidence
from other studies that COX-1-derived eicosanoids, such as
TxA2, augment the response to hypertensive stimuli (Francois
et al., 2004), this was not true of the hypertension resultant
from PGI2 deficiency. Despite a lack of an effect on blood pres-
sure, our results suggest that blocking TP receptors, or per-
haps reducing TxA2 generation by low-dose aspirin, might pro-
tect against cardiac end-organ damage associated with the
predominant reduction of PGI2 associated with COX-2 inhibi-
tion. However, the practical utility of such an approach would
require demonstration that GI protection is retained.
Experimental procedures
Mouse lines
Mice with targeted disruptions of the Ip and Tp genes were generated as
described previously (Cheng et al., 2002; Thomas et al., 1998). As both
mutations were originally generated in embryonic stem cells derived from
129 mice, chimeras were initially crossed with 129/SvEv females to immedi-
ately generate progeny bearing either the Ip or Tp mutations on a homogen-
eous 129 background. Double-knockout mice (IPTP DKO) were generated
by intercrossing the IP- and TP-deficient lines. In our experiments, 129 wt
littermates were used as controls. Animals were maintained in the animal
facility of the Durham VA Medical Center, and experimental procedures de-
scribed below were approved by the Institutional Animal Care and Use
Committees of the Durham VA and Duke University Medical Centers. The
studies were limited to male mice.
Blood-pressure measurements in conscious mice
Systolic blood pressures were measured in conscious mice using a compu-
terized tail-cuff system after 2 weeks of daily training, as described pre-
viously (Ito et al., 1995; Krege et al., 1995). Data were recorded at baseline
for 3 weeks (one set of 10 measurements per day). Measurements with a
standard deviation of more than 20 mm Hg for the systolic blood pressure
were discarded. This method has been extensively validated and correlates
well with direct measurements of intra-arterial pressure (Ito et al., 1995;
Krege et al., 1995). Baseline measurements were carried out on conven-
tional mouse chow (0.4% NaCl). To determine the effects of altered dietary
salt intake on blood pressure, mice were first fed a low-salt diet (<0.02%
NaCl, Harlan Teklad, Wisconsin) for 3 weeks while systolic blood pressure
was recorded daily as described above. After a washout period of feeding
the conventional (0.4% NaCl) diet for one week, mice were then fed a high-
salt diet (6% NaCl, Harlan Teklad) for 3 weeks while their systolic blood
pressure was measured daily.
Echocardiography
Transthoracic 2D guided M-mode echocardiography was performed in con-
scious mice using an HDI 5000 echocardiograph (ATL, Bothell, Washington)
as previously described (Esposito et al., 2000). The following parameters
were measured: LVEDD, LV end-diastolic dimension; LVESD, LV end-205
S H O R T A R T I C L Esystolic dimension; FS, fractional shortening calculated as (LVEDD-LVESD)/
LVEDD. The individual performing the echocardiograms was blinded to the
experimental groups.
Analysis of cardiac histopathology
At 3, 6, and 17 months of age, hearts were excised from mice and immedi-
ately weighed. The tissue was fixed in 10% formalin containing PBS, em-
bedded in paraffin, and 4 m sections were stained with Masson’s tri-
chrome to highlight extracellular matrix deposition. Digital images were
captured using an Olympus (Melville, New York) BX40 microscope and an
Optronics (Goleta, California) DEI 750 3 CCD digital camera. The digital
images were analyzed using Optimas v6.5 image analysis software (Media
Cybernetics, Del Mar, California) by keying on color-specific features. Two
color parameters were measured representing fibrosis (green color spec-
trum) and cardiac muscle (red color spectrum). The collagen fraction was
calculated as the ratio of the sum of the total area of interstitial fibrosis to
the sum of the interstitial fibrosis tissue area plus the myocyte area in the
entire visual field of the section. All procedures and measurements were
performed twice for each histologic cross-section and then averaged. Two
surgical pathologists analyzed the slides without knowledge of the experi-
mental groups.
Hydralazine treatment
Beginning at 3 months of age, a separate group of male Ip−/− mice were
treated with hydralazine (150 mg/kg/day, Sigma Chemical) in drinking water
for 3 months. Blood pressures were measured before and during hydrala-
zine treatment. At the end of the study period, heart weights and cardiac
fibrosis were measured as described above.
Measurement of renin mRNA
Relative levels of mRNA for renin were determined by real-time (RT) PCR
with the ABI Prism 7700 Sequence Detection System as described pre-
viously (Crowley et al., 2005). Kidneys were harvested from IPKO and wt
mice fed a control (0.4% NaCl) diet, and total RNA was isolated in using an
RNeasy Mini Kit per the manufacturer’s instructions (Qiagen Inc., Valencia,
California). RT-PCR amplifications were performed in a 96-well plate in the
ABI Prism 7700 sequence detector (PE-Biosystem Inc., Foster City, Cali-
fornia). During the amplification, the fluorescence of FAM (or TET), TAMRA,
and ROX (a passive reference dye) was measured by the 7700 sequence
detector in each well of the 96-well plate. The numbers of copies of the
PCR template in the starting sample were calculated using the Sequence
Detector Software (SDS) incorporated in the ABI Prism 7700 Sequence De-
tector System. A standard plasmid containing a DNA fragment for the renin
gene was used as an external control, and amplification of the β-actin gene
was used as an endogenous control. For each experimental sample, the
amounts of the target and of the endogenous control were determined from
the appropriate standard curves.
Urinary excretion of aldosterone and TxB2
Mice were individually housed in specially designed metabolic cages that
accommodate individual mice with free access to tap water. Twenty-four
hour urine was collected in wt and IPKO mice fed a control (0.4% NaCl)
diet. Urine was clarified by 15 min of centrifugation (14000 g). Urinary aldos-
terone concentrations were determined by radioimmunoassay according to
the manufacturer’s instructions (Diagnostic Labs). TxB2 was measured
using an ELISA assay on fresh urine samples (Cayman Chemical, Ann Arbor,
Michigan). Urine creatinine concentration was quantified using the alkaline
picrate method (The Creatinine Companion, Exocell Inc.).
Statistical analysis
Data are expressed as mean ± SEM. Data were analyzed using paired or
unpaired Student’s t test for parametric variables and Mann-Whitney or
Fisher χ2 test for nonparametric variables.
Acknowledgments
During the last 5 years, G.A.F. has consulted for Merck, GSK, Pfizer, Bayer,
Johnson & Johnson, Novartis, CV Therapeutics, Altana, Boehringer Ingel-
heim, Fujisawa, Tanabe, Portola, and Nicox. T.M.C. has consulted for
Merck, Merck Frosst, and Pfizer. This work was supported by funding from206the Medical Research Service of the Veterans Administration and by Na-
tional Institutes of Health Grant DK069896 (B.H.K. and T.M.C.).
Received: May 31, 2005
Revised: July 1, 2005
Accepted: August 16, 2005
Published: September 13, 2005
References
Athirakul, K., Kim, H.-S., Audoly, L., Smithies, O., and Coffman, T. (2001).
Deficiency of COX-1 causes natriuresis and enhanced sensitivity to ACE
inhibition. Kidney Int. 60, 2324–2329.
Aw, T.J., Haas, S.J., Liew, D., and Krum, H. (2005). Meta-analysis of
COX-2 inhibitors and their effects on blood pressure. Arch. Intern. Med.
165, 490–496.
Bruggeman, L.A., Pellicoro, J.A., Horigan, E.A., and Klotman, P.E. (1993).
Thromboxane and prostacyclin differentially regulate murine extracellular
matrix gene expression. Kidney Int. 43, 1219–1225.
Cheng, Y., Austin, S.C., Rocca, B., Koller, B.H., Coffman, T.M., Grosser,
T., Lawson, J.A., and FitzGerald, G.A. (2002). Role of prostacyclin in the
cardiovascular response to thromboxane A2. Science 296, 539–541.
Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A.,
Izzo, J.L., Jones, D.W., Materson, B.J., Oparil, S., Wright, J.T., Jr., and Roc-
cella, E.J. (2003). Seventh report of the joint national committee on preven-
tion, detection, evaluation, and treatment of high blood pressure. Hyperten-
sion 42, 1206–1252.
Conlin, P., Moore, T.J., Swartz, S.L., Barr, E., Gazdick, L., Fletcher, C., De-
Lucca, P., and Demopoulos, L. (2000). Effect of indomethacin on blood
pressure lowering by captopril and losartan. Hypertension 36, 461–465.
Crowley, S., Gurley, S., Oliverio, M., Pazmino, A., Griffiths, R., Flannery, P.,
Spurney, R., Kim, H.-S., Smithies, O., Le, T., and Coffman, T. (2005). Distinct
roles for the kidney and systemic tissues in blood pressure regulation by
the renin-angiotensin system. J. Clin. Invest. 115, 1092–1099.
Egan, K.M., Lawson, J.A., Fries, S., Koller, B.H., Rader, D.J., Smyth, E.M.,
and FitzGerald, G.A. (2004). COX-2-derived prostacyclin confers atheropro-
tection on female mice. Science 306, 1954–1957.
Esposito, G., Santana, L.F., Dilly, K., Cruz, J.D., Mao, L., Lederer, W.J., and
Rockman, H.A. (2000). Cellular and functional defects in a mouse model of
heart failure. Am. J. Physiol. Heart Circ. Physiol. 279, H3101–H3112.
FitzGerald, G.A. (2004). Coxibs and cardiovascular disease. N. Engl. J. Med.
351, 1709–1711.
FitzGerald, G.A., and Patrono, C. (2001). The coxibs, selective inhibitors of
cyclooxygenase-2. N. Engl. J. Med. 345, 433–442.
Francois, H., Athirakul, K., Mao, L., Rockman, H., and Coffman, T.M. (2004).
Role for thromboxane receptors in angiotensin-II-induced hypertension. Hy-
pertension 43, 364–369.
Fujino, T., Nakagawa, N., Koh-ichi, Y., Hara, A., Yamada, T., Takayama, K.,
Kuriyama, S., Hosoki, Y., Takahata, O., Taniguchi, T., et al. (2004). De-
creased susceptibility to renovascular hypertension in mice lacking the
prostaglandin I2 receptor IP. J. Clin. Invest. 114, 805–812.
Gerber, J.G., Keller, R.T., and Nies, A.S. (1979). Prostaglandins and renin
release: the effect of PGI2, PGE2, and 13,14-dihydro PGE2 on the barore-
ceptor mechanism of renin release in the dog. Circ. Res. 44, 796–799.
Gross, V., and Luft, F. (2003). Exercising restraint in measuring blood pres-
sure in conscious mice. Hypertension 41, 37–41.
Gurwitz, J.H., Avorn, J., Bohn, R.L., Glynn, R.J., Monane, M., and Mogun,
H. (1994). Initiation of antihypertensive treatment during nonsteroidal anti-
inflammatory drug therapy. JAMA 272, 781–786.
Hilchey, S.D., and Bell-Quilley, C.P. (1995). Association between the natri-
uretic action of angiotensin-(1–7) and selective stimulation of renal prosta-
glandin I2 release. Hypertension 25, 1238–1244.CELL METABOLISM : SEPTEMBER 2005
Hypertension and heart fibrosis in IP deficiencyHill, T.W., and Moncada, S. (1979). The renal haemodynamic and excretory
actions of prostacyclin and 6-oxo-PGF1 alpha in anaesthetized dogs. Pros-
taglandins 17, 87–98.
Ito, M., Oliverio, M.I., Mannon, P.J., Best, C.F., Maeda, N., Smithies, O., and
Coffman, T.M. (1995). Regulation of blood pressure by the type 1A angio-
tensin II receptor gene. Proc. Natl. Acad. Sci. USA 92, 3521–3525.
Johnson, A.G., Nguyen, T.V., and Day, R.O. (1994). Do nonsteroidal anti-
inflammatory drugs affect blood pressure? A meta-analysis. Ann. Intern.
Med. 121, 289–300.
Klug, D., Robert, V., and Swynghedauw, B. Suppl(1993). Role of mechanical
and hormonal factors in cardiac remodeling and the biological limits of myo-
cardial adaptation. Am. J. Cardiol. 71, 46A–54A.
Krege, J.H., Hodgin, J.B., Hagaman, J.R., and Smithies, O. (1995). A nonin-
vasive computerized tail-cuff system for measuring blood pressure in mice.
Hypertension 25, 1111–1115.
McAdam, B.F., Catella-Lawson, F., Mardini, I.A., Kapoor, S., Lawson, J.A.,
and FitzGerald, G.A. (1999). Systemic biosynthesis of prostacyclin by cyclo-
oxygenase (COX)-2: the human pharmacology of a selective inhibitor of
COX-2. Proc. Natl. Acad. Sci. USA 96, 272–277.
Murata, T., Ushikubi, F., Matsuoka, T., Hirata, M., Yamasaki, A., Sugimoto,
Y., Ichikawa, A., Aze, Y., Tanaka, T., Yoshida, N., et al. (1997). Altered pain
perception and inflammatory response in mice lacking prostacyclin recep-
tor. Nature 388, 678–682.
Pope, J.E., Anderson, J.J., and Felson, D.T. (1993). A meta-analysis of the
effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch.
Intern. Med. 153, 477–484.
Qi, Z., Hao, C.M., Langenbach, R.I., Breyer, R.M., Redha, R., Morrow, J.D.,
and Breyer, M.D. (2002). Opposite effects of cyclooxygenase-1 and -2 activ-
ity on the pressor response to angiotensin II. J. Clin. Invest. 110, 61–69.
Ryan, M.J., Didion, S.P., Davis, D.R., Faraci, F.M., and Sigmund, C.D. (2002).
Endothelial dysfunction and blood pressure variability in selected inbred
mouse strains. Arterioscler. Thromb. Vasc. Biol. 22, 42–48.CELL METABOLISM : SEPTEMBER 2005Smith, W. (1992). Prostanoid biosynthesis and mechanisms of action. Am.
J. Physiol. 263, F181–F191.
Thomas, D.W., Mannon, R.B., Mannon, P.J., Latour, A., Oliver, J.A., Hoff-
man, M., Smithies, O., Koller, B.H., and Coffman, T.M. (1998). Coagulation
defects and altered hemodynamic responses in mice lacking receptors for
thromboxane A2. J. Clin. Invest. 102, 1994–2001.
Thomas, D.W., Rocha, P., Nataraj, C., Robinson, L., Koller, B.H., and Coff-
man, T.M. (2003). Pro-inflammatory actions of thromboxane receptors to
enhance cellular immune responses. J. Immunol. 171, 6389–6395.
Verdecchia, P., Porcellati, C., Reboldi, G., Gattobigio, R., Borgioni, C., Pear-
son, T., and Ambrosio, G. (2001). Left ventricular hypertrophy as an inde-
pendent predictor of acute cerebrovascular events in essential hyperten-
sion. Circulation 104, 2039–2044.
Wang, Q., Hummler, E., Nussberger, J., Clement, S., Gabbiani, G., Brunner,
H.R., and Burnier, M. (2002). Blood pressure, cardiac, and renal responses
to salt and deoxycorticosterone acetate in mice: role of Renin genes. J. Am.
Soc. Nephrol. 13, 1509–1516.
Watanabe, H., Katoh, T., Eiro, M., Iwamoto, M., Ushikubi, F., Narumiya, S.,
and Watanabe, T. (2005). Effects of salt loading on blood pressure in mice
lacking the prostanoid receptor gene. Circ. J. 69, 124–126.
Weber, K.T., and Brilla, C.G. (1991). Pathological hypertrophy and cardiac
interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation
83, 1849–1865.
Weinberger, M.H. (1996). Salt sensitivity of blood pressure in humans. Hy-
pertension 27, 481–490.
Wong, A., Kulandavelu, S., Whiteley, K., Qu, D., Lowell Langille, B., and
Adamson, S. (2002). Maternal cardiovascular changes during pregnancy
and postpartum in mice. Am. J. Physiol. 282, H918–H925.
Xiao, C.Y., Hara, A., Yuhki, K., Fujino, T., Ma, H., Okada, Y., Takahata, O.,
Yamada, T., Murata, T., Narumiya, S., and Ushikubi, F. (2001). Roles of pros-
taglandin I(2) and thromboxane A(2) in cardiac ischemia-reperfusion injury:
a study using mice lacking their respective receptors. Circulation 104,
2210–2215.207
